Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Show More...

  • Website https://www.prothena.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 3.86 EUR
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -0.71 -1.68 -2.84 -2.2 -0.29 -2.66 -4.66 -4.07 -3.93 -1.95 -2.02
    Dividends USD
    Payout Ratio % *
    Shares Mil 18.0 18.0 15.0 19.0 25.0 30.0 34.0 38.0 40.0 40.0 40.0
    Book Value Per Share * EUR 3.28 9.06 10.9 10.92 9.71 7.45 6.48 5.77
    Free Cash Flow Per Share * EUR -1.62 0.05 -1.74 -3.19 -3.13 -1.06 -1.38
    Return on Assets % -820.07 -62.32 -26.31 -2.94 -23.39 -37.89 -32.05 -31.28 -16.92 -18.72
    Financial Leverage (Average) 1.02 1.05 1.05 1.07 1.26 1.22 1.54 1.54 1.57
    Return on Equity % -68.99 -27.35 -3.09 -24.78 -44.1 -39.67 -42.63 -26.07 -28.34
    Return on Invested Capital % -69.0 -27.39 -3.12 -24.84 -38.64 -34.92 -37.97 -25.31 -28.12
    Interest Coverage -41.73 -41.23
    Current Ratio 0.010 72.16 24.06 24.86 16.99 9.53 11.4 28.9 21.36 21.05
    Quick Ratio 71.72 23.86 24.53 16.7 9.42 11.18 28.65 21.21 20.65
    Debt/Equity 0.14 0.13 0.15 0.07 0.06